ipos0_l

FDA expands indication for Eylea to cover all stages of diabetic retinopathy

pharmafile | May 14, 2019 | News story | Manufacturing and Production |  Bayer, Eylea, FDA, Regeneron, approval, pharma 

The FDA has expanded the indication for Regeneron’s Eylea (aflibercept) to include all stages of diabetic retinopathy.

Regeneron chief scientific officer George Yancopoulos commented: “with today’s FDA approval, Eylea has once again set a high bar for the treatment of diabetic eye diseases.”

The approval was backed by data from the Phase 3 PANORAMA trial of 402 patients. The study found 80% of patients who received the drug every eight weeks experienced an at least 2-step improvement in the Diabetic Retinopathy Severity Scale score versus baseline, compared with 15 percent for placebo.  

Advertisement

Eylea was first approved in the US for the treatment of wet age-related macular degeneration in 2011.  

The drug is now being studied as a cancer treatment and being co-developed by Bayer and Regeneron for eye diseases.

Louis Goss

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

FDA grants De Novo authorisation to light-filtering device for migraine

The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …

The Gateway to Local Adoption Series

Latest content